Cargando…
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma
Pancreas ductal adenocarcinoma lacks predictive biomarkers. CD40 is a member of the tumor necrosis factor superfamily. CD40–sCD40L interaction is considered to contribute to the promotion of tumor cell growth and angiogenesis. The aim of the present study was to investigate the role of serum sCD40L...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968860/ https://www.ncbi.nlm.nih.gov/pubmed/27555786 http://dx.doi.org/10.2147/OTT.S106496 |
_version_ | 1782445720146542592 |
---|---|
author | Azzariti, Amalia Brunetti, Oronzo Porcelli, Letizia Graziano, Giusi Iacobazzi, Rosa Maria Signorile, Michele Scarpa, Aldo Lorusso, Vito Silvestris, Nicola |
author_facet | Azzariti, Amalia Brunetti, Oronzo Porcelli, Letizia Graziano, Giusi Iacobazzi, Rosa Maria Signorile, Michele Scarpa, Aldo Lorusso, Vito Silvestris, Nicola |
author_sort | Azzariti, Amalia |
collection | PubMed |
description | Pancreas ductal adenocarcinoma lacks predictive biomarkers. CD40 is a member of the tumor necrosis factor superfamily. CD40–sCD40L interaction is considered to contribute to the promotion of tumor cell growth and angiogenesis. The aim of the present study was to investigate the role of serum sCD40L as a predictor in metastatic pancreatic cancer. We evaluated 27 consecutive pancreatic cancer patients treated with FOLFIRINOX (21 patients) or gemcitabine plus nab-paclitaxel combination (six patients). The sCD40L level was measured in serum by enzyme-linked immunosorbent assay at baseline, at first evaluation (all patients), and at time to progression (18 patients). The radiological response was evaluated according to the Response Evaluation Criteria in Solid Tumors, Version 1.1. The Wilcoxon signed-rank test was used to compare pre–post treatment sCD40L levels with respect to clinical response, while Pearson’s correlation coefficient was used for the correlation between sCD40L and CA19.9 pre- and post-treatment. The Kruskal–Wallis test was also conducted for further comparisons. We observed a statistically significant reduction in the sCD40L level after 3 months of treatment in patients with partial response (11,718.05±7,097.13 pg/mL vs 4,689.42±5,409.96 pg/mL; P<0.01). Conversely, in patients with progressive disease, the biomarker statistically increased in the same time (9,351.51±7,356.91 pg/mL vs 22,282.92±11,629.35 pg/mL; P<0.01). This trend of sCD40L was confirmed in 18 patients at time to progression after the first evaluation. No differences were recorded within the stable disease group. Moreover, there was a positive correlation between the sCD40L and CA19.9 pre–post treatment variation percentage (Pearson’s correlation coefficient =0.52; P<0.05). Our data suggest a possible predictive role of sCD40L in pancreatic cancer patients, similar to CA19.9. |
format | Online Article Text |
id | pubmed-4968860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49688602016-08-23 Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma Azzariti, Amalia Brunetti, Oronzo Porcelli, Letizia Graziano, Giusi Iacobazzi, Rosa Maria Signorile, Michele Scarpa, Aldo Lorusso, Vito Silvestris, Nicola Onco Targets Ther Original Research Pancreas ductal adenocarcinoma lacks predictive biomarkers. CD40 is a member of the tumor necrosis factor superfamily. CD40–sCD40L interaction is considered to contribute to the promotion of tumor cell growth and angiogenesis. The aim of the present study was to investigate the role of serum sCD40L as a predictor in metastatic pancreatic cancer. We evaluated 27 consecutive pancreatic cancer patients treated with FOLFIRINOX (21 patients) or gemcitabine plus nab-paclitaxel combination (six patients). The sCD40L level was measured in serum by enzyme-linked immunosorbent assay at baseline, at first evaluation (all patients), and at time to progression (18 patients). The radiological response was evaluated according to the Response Evaluation Criteria in Solid Tumors, Version 1.1. The Wilcoxon signed-rank test was used to compare pre–post treatment sCD40L levels with respect to clinical response, while Pearson’s correlation coefficient was used for the correlation between sCD40L and CA19.9 pre- and post-treatment. The Kruskal–Wallis test was also conducted for further comparisons. We observed a statistically significant reduction in the sCD40L level after 3 months of treatment in patients with partial response (11,718.05±7,097.13 pg/mL vs 4,689.42±5,409.96 pg/mL; P<0.01). Conversely, in patients with progressive disease, the biomarker statistically increased in the same time (9,351.51±7,356.91 pg/mL vs 22,282.92±11,629.35 pg/mL; P<0.01). This trend of sCD40L was confirmed in 18 patients at time to progression after the first evaluation. No differences were recorded within the stable disease group. Moreover, there was a positive correlation between the sCD40L and CA19.9 pre–post treatment variation percentage (Pearson’s correlation coefficient =0.52; P<0.05). Our data suggest a possible predictive role of sCD40L in pancreatic cancer patients, similar to CA19.9. Dove Medical Press 2016-07-28 /pmc/articles/PMC4968860/ /pubmed/27555786 http://dx.doi.org/10.2147/OTT.S106496 Text en © 2016 Azzariti et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Azzariti, Amalia Brunetti, Oronzo Porcelli, Letizia Graziano, Giusi Iacobazzi, Rosa Maria Signorile, Michele Scarpa, Aldo Lorusso, Vito Silvestris, Nicola Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma |
title | Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma |
title_full | Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma |
title_fullStr | Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma |
title_full_unstemmed | Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma |
title_short | Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma |
title_sort | potential predictive role of chemotherapy-induced changes of soluble cd40 ligand in untreated advanced pancreatic ductal adenocarcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968860/ https://www.ncbi.nlm.nih.gov/pubmed/27555786 http://dx.doi.org/10.2147/OTT.S106496 |
work_keys_str_mv | AT azzaritiamalia potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma AT brunettioronzo potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma AT porcelliletizia potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma AT grazianogiusi potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma AT iacobazzirosamaria potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma AT signorilemichele potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma AT scarpaaldo potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma AT lorussovito potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma AT silvestrisnicola potentialpredictiveroleofchemotherapyinducedchangesofsolublecd40ligandinuntreatedadvancedpancreaticductaladenocarcinoma |